Clinical Trial

Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets

Recruiting
View on ClinicalTrials.gov →
Summary
This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-06.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT07023172
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Type 2 Diabetes
Enrollment 3,000 participants
Start Date 2025-05-30
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-05